Alzheimer's disease is a progressive neurodegenerative disease characterized by the accumulation of amyloid-β (Aβ) in the brain. Aβ oligomers are believed to cause synapse damage resulting in the memory deficits that are characteristic of this disease. Since the loss of synaptic proteins in the brain correlates closely with the degree of dementia in Alzheimer's disease, the process of Aβ-induced synapse damage was investigated in cultured neurons by measuring the loss of synaptic proteins. Soluble Aβ oligomers, derived from Alzheimer's-affected brains, caused the loss of cysteine string protein and synaptophysin from neurons. When applied to synaptosomes Aβ oligomers increased cholesterol concentrations and caused aberrant activation of cytoplasmic phospholipase A 2 (cPLA 2 ). In contrast, Aβ monomer preparations did not affect cholesterol concentrations or activate synaptic cPLA 2 , nor did they damage synapses. The Aβ oligomer-induced aggregation of cellular prion proteins (PrP C ) at synapses triggered the activation of cPLA 2 that leads to synapse degeneration. Critically, Aβ monomer preparations did not cause the aggregation of PrP C ; rather they reduced the Aβ oligomer-induced aggregation of PrP C . The presence of Aβ monomer preparations also inhibited the Aβ oligomer-induced increase in cholesterol concentrations and activation of cPLA 2 in synaptosomes and protected neurons against the Aβ oligomer-induced synapse damage. These results support the hypothesis that Aβ monomers are neuroprotective. We hypothesise that synapse damage may result from a pathological Aβ monomer:oligomer ratio rather than the total concentrations of Aβ within the brain.
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Introduction
Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia resulting from synapse failure (Selkoe, 2002; Tanzi, 2005) . The amyloid hypothesis maintains that the pivotal event in AD is the production of amyloid-β (Aβ) peptides following the proteolytic cleavage of the amyloid precursor protein (APP) (De Strooper et al., 2010; Hardy and Selkoe, 2002) . The accumulation of C-terminal fragments (Aβ) within the brain is thought to cause the synapse dysfunction and the memory loss that is characteristic of AD. Aβ has the capacity to self-aggregate, and consequently is found in different forms ranging from monomers and small soluble oligomers to much larger fibrils and plaques. The soluble Aβ oligomers are currently considered to be the principal mediators of synapse damage (Yang et al., 2017) .
The mechanisms of Alzheimer's-related synapse damage can be examined by incubation of cultured neurons with Aβ. Since the loss of synapses and synaptic proteins is a feature of AD that strongly correlates with cognitive decline in AD (Counts et al., 2006; Masliah et al., 1991; Reddy et al., 2005) synapse density was measured by determining the amounts of synaptophysin and cysteine string protein (CSP) in cultured neurons (Lipton et al., 2001) . Soluble forms of Aβ derived from the brains Alzheimer's patients caused synapse degeneration in neurons (Yang et al., 2017) . The biological effects of these Aβ oligomers occurred at picomolar concentrations, similar concentrations to those found in the cerebrospinal fluid of Alzheimer's patients (Bibl et al., 2007; McLean et al., 1999; Mehta et al., 2000) . The role of Aβ monomers that are found in high concentrations in the brain are poorly understood; while some studies report that Aβ monomers are not toxic (Shankar et al., 2007; Walsh et al., 2002) another study suggested that they were neuroprotective (Giuffrida et al., 2009) . Confusion may arise due to the heterogeneity of Aβ in monomer preparations, in addition to
